EVFM's Business Model
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.evofem.com |
| CEO (Chief Executive Officer) | Saundra Pelletier |
| Number of Employees | |
| IPO date | November 20, 2014 |
EVFM Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 12400 High Bluff Drive |
| City | San Diego |
| State | CA |
| Phone | 858 550 1900 |
| Zip Code | 92130 |
| Other Identifiers | |
| CIK | 0001618835 |
| ISIN | US30048L3024 |
| CUSIP | 30048L104 |
| Open | 0.0086 |
| Previous Close | 0.009 |
| Volume | 65.3 Thou. |
| Average Volume | 270.4 Thou. |
| Day’s Range | 0.0085 – 0.009 |
| 52 Week Range | 0.007-0.02 |
| MA (50) | 0.00904 |
| MA (200) | 0.01008 |
| Market Cap | 1.14 Mil. |
| Shares Out. | 126.7 Mil. |
| Earnings Date | Apr 30, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
